Tirzepatide in overweight or obesity with PCOS-related ovarian dysfunction (PERIODS)

Phase 4, randomised, double-blind trial in polycystic ovary syndrome (PCOS), obesity and Overweight comparing Tirzepatide with Placebo comparator (2 arms). Primary endpoints: Mean menstrual bleeding ratio during the last 52 weeks of treatment and Change in menstrual bleeding ratio from baseline. Planned start Dec 2025; status: authorised.